Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis

Ema Robinson, Kelvin Macdonald, Kai Slaughter, Madison McKinney, Siddharth Patel, Conroy Sun, Gaurav Sahay

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR). mRNA therapy via nanoparticle delivery represents a powerful technology for the transfer of genetic material to cells with large, widespread populations, such as airway epithelia. We deployed a clinically relevant lipid-based nanoparticle (LNP) for packaging and delivery of large chemically modified CFTR mRNA (cmCFTR) to patient-derived bronchial epithelial cells, resulting in an increase in membrane-localized CFTR and rescue of its primary function as a chloride channel. Furthermore, nasal application of LNP-cmCFTR restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR knockout mice for at least 14 days. On day 3 post-transfection, CFTR activity peaked, recovering up to 55% of the net chloride efflux characteristic of healthy mice. This magnitude of response is superior to liposomal CFTR DNA delivery and is comparable with outcomes observed in the currently approved drug ivacaftor. LNP-cmRNA-based systems represent a powerful platform technology for correction of cystic fibrosis and other monogenic disorders. The use of lipid nanoparticles to deliver therapeutic mRNA is an increasingly attractive gene therapy modality. Here, Robinson et al. demonstrate that lipid nanoparticle transfection of mRNA can repair the central defect in cystic fibrosis, chloride transport, both in vitro and in vivo. The authors discuss why this technology is a promising treatment option for monogenic disorders such as cystic fibrosis.

    Original languageEnglish (US)
    JournalMolecular Therapy
    DOIs
    StateAccepted/In press - Jan 1 2018

    Fingerprint

    Cystic Fibrosis Transmembrane Conductance Regulator
    Cystic Fibrosis
    Nanoparticles
    Chlorides
    Lipids
    Messenger RNA
    Genetic Therapy
    Transfection
    Epithelium
    Technology
    Technology Transfer
    Chloride Channels
    Product Packaging
    Therapeutics
    Nose
    Knockout Mice
    Epithelial Cells
    Membranes
    DNA
    Pharmaceutical Preparations

    Keywords

    • cystic fibrosis
    • gene therapy
    • ion transport
    • mRNA therapeutics
    • nanoparticles
    • nasal potential difference

    ASJC Scopus subject areas

    • Molecular Medicine
    • Molecular Biology
    • Genetics
    • Pharmacology
    • Drug Discovery

    Cite this

    Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. / Robinson, Ema; Macdonald, Kelvin; Slaughter, Kai; McKinney, Madison; Patel, Siddharth; Sun, Conroy; Sahay, Gaurav.

    In: Molecular Therapy, 01.01.2018.

    Research output: Contribution to journalArticle

    Robinson, Ema ; Macdonald, Kelvin ; Slaughter, Kai ; McKinney, Madison ; Patel, Siddharth ; Sun, Conroy ; Sahay, Gaurav. / Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. In: Molecular Therapy. 2018.
    @article{ad801dcfb2014e57bc11a07e0e62761e,
    title = "Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis",
    abstract = "The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR). mRNA therapy via nanoparticle delivery represents a powerful technology for the transfer of genetic material to cells with large, widespread populations, such as airway epithelia. We deployed a clinically relevant lipid-based nanoparticle (LNP) for packaging and delivery of large chemically modified CFTR mRNA (cmCFTR) to patient-derived bronchial epithelial cells, resulting in an increase in membrane-localized CFTR and rescue of its primary function as a chloride channel. Furthermore, nasal application of LNP-cmCFTR restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR knockout mice for at least 14 days. On day 3 post-transfection, CFTR activity peaked, recovering up to 55{\%} of the net chloride efflux characteristic of healthy mice. This magnitude of response is superior to liposomal CFTR DNA delivery and is comparable with outcomes observed in the currently approved drug ivacaftor. LNP-cmRNA-based systems represent a powerful platform technology for correction of cystic fibrosis and other monogenic disorders. The use of lipid nanoparticles to deliver therapeutic mRNA is an increasingly attractive gene therapy modality. Here, Robinson et al. demonstrate that lipid nanoparticle transfection of mRNA can repair the central defect in cystic fibrosis, chloride transport, both in vitro and in vivo. The authors discuss why this technology is a promising treatment option for monogenic disorders such as cystic fibrosis.",
    keywords = "cystic fibrosis, gene therapy, ion transport, mRNA therapeutics, nanoparticles, nasal potential difference",
    author = "Ema Robinson and Kelvin Macdonald and Kai Slaughter and Madison McKinney and Siddharth Patel and Conroy Sun and Gaurav Sahay",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1016/j.ymthe.2018.05.014",
    language = "English (US)",
    journal = "Molecular Therapy",
    issn = "1525-0016",
    publisher = "Nature Publishing Group",

    }

    TY - JOUR

    T1 - Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis

    AU - Robinson, Ema

    AU - Macdonald, Kelvin

    AU - Slaughter, Kai

    AU - McKinney, Madison

    AU - Patel, Siddharth

    AU - Sun, Conroy

    AU - Sahay, Gaurav

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR). mRNA therapy via nanoparticle delivery represents a powerful technology for the transfer of genetic material to cells with large, widespread populations, such as airway epithelia. We deployed a clinically relevant lipid-based nanoparticle (LNP) for packaging and delivery of large chemically modified CFTR mRNA (cmCFTR) to patient-derived bronchial epithelial cells, resulting in an increase in membrane-localized CFTR and rescue of its primary function as a chloride channel. Furthermore, nasal application of LNP-cmCFTR restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR knockout mice for at least 14 days. On day 3 post-transfection, CFTR activity peaked, recovering up to 55% of the net chloride efflux characteristic of healthy mice. This magnitude of response is superior to liposomal CFTR DNA delivery and is comparable with outcomes observed in the currently approved drug ivacaftor. LNP-cmRNA-based systems represent a powerful platform technology for correction of cystic fibrosis and other monogenic disorders. The use of lipid nanoparticles to deliver therapeutic mRNA is an increasingly attractive gene therapy modality. Here, Robinson et al. demonstrate that lipid nanoparticle transfection of mRNA can repair the central defect in cystic fibrosis, chloride transport, both in vitro and in vivo. The authors discuss why this technology is a promising treatment option for monogenic disorders such as cystic fibrosis.

    AB - The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR). mRNA therapy via nanoparticle delivery represents a powerful technology for the transfer of genetic material to cells with large, widespread populations, such as airway epithelia. We deployed a clinically relevant lipid-based nanoparticle (LNP) for packaging and delivery of large chemically modified CFTR mRNA (cmCFTR) to patient-derived bronchial epithelial cells, resulting in an increase in membrane-localized CFTR and rescue of its primary function as a chloride channel. Furthermore, nasal application of LNP-cmCFTR restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR knockout mice for at least 14 days. On day 3 post-transfection, CFTR activity peaked, recovering up to 55% of the net chloride efflux characteristic of healthy mice. This magnitude of response is superior to liposomal CFTR DNA delivery and is comparable with outcomes observed in the currently approved drug ivacaftor. LNP-cmRNA-based systems represent a powerful platform technology for correction of cystic fibrosis and other monogenic disorders. The use of lipid nanoparticles to deliver therapeutic mRNA is an increasingly attractive gene therapy modality. Here, Robinson et al. demonstrate that lipid nanoparticle transfection of mRNA can repair the central defect in cystic fibrosis, chloride transport, both in vitro and in vivo. The authors discuss why this technology is a promising treatment option for monogenic disorders such as cystic fibrosis.

    KW - cystic fibrosis

    KW - gene therapy

    KW - ion transport

    KW - mRNA therapeutics

    KW - nanoparticles

    KW - nasal potential difference

    UR - http://www.scopus.com/inward/record.url?scp=85048094730&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85048094730&partnerID=8YFLogxK

    U2 - 10.1016/j.ymthe.2018.05.014

    DO - 10.1016/j.ymthe.2018.05.014

    M3 - Article

    C2 - 29910178

    AN - SCOPUS:85048094730

    JO - Molecular Therapy

    JF - Molecular Therapy

    SN - 1525-0016

    ER -